NEUROLOGY PHASE II
Steering Committee Meeting
October 3-4, 2012

National Quality Forum
Executive Building
1030 15th Street, NW, Suite 900
Washington, DC 20005
(202) 783-1300

DRAFT AGENDA

Day 1: October 3, 2012

9:00am  Welcome
David Knowlton, MA, Co-chair
David Tirschwell, MD, Co-chair
Karen Johnson, MS, Senior Director

9:10am  Introductions and Disclosure of Interest
Ann Hammersmith, JD, General Counsel

9:25am  Project Introduction and Overview of Evaluation Process
Karen Johnson, MS, Senior Director
Suzanne Theberge, MPH, Project Manager

9:40am  Consideration of Candidate Measures
  • 2111: Antipsychotic Use in Persons with Dementia (Pharmacy Quality Alliance)
  • 2091: Persistent Indicators of Dementia without a Diagnosis—Long Stay (AMDA)
  • 2092: Persistent Indicators of Dementia without a Diagnosis—Short Stay (AMDA)

11:00am Break

11:15am  Consideration of Candidate Measures (Continued)
  • 1973: Annual Parkinson’s Disease Diagnosis Review (AAN)
  • 1982: Parkinson’s Disease Psychiatric Disorders or Disturbance Assessment (AAN)
• 1983: Parkinson’s Disease Cognitive Impairment or Dysfunction Assessment (AAN)

12:15pm  **NQF Member and Public Comment**

12:30pm  **Lunch**

1:15pm  **Consideration of Candidate Measures (Continued)**
• 1985: Parkinson’s Disease: Querying About Sleep Disturbances (AAN)
• 1988: Parkinson’s Disease Rehabilitative Therapy Options (AAN)
• 1989: Parkinson’s Disease Medical and Surgical Treatment Options Reviewed (AAN)

3:00pm  **Break**

3:15pm  **Consideration of Candidate Measures (Continued)**
• 1814: Counseling for Women of Childbearing Potential with Epilepsy (American Academy of Neurology [AAN])
• 1953: Seizure type(s) and current seizure frequency(ies) (AAN)
• 1954: Documentation of Etiology of Epilepsy or Epilepsy Syndrome (AAN)

4:45pm  **NQF Member and Public Comment**

5:00 pm  **Adjourn**

---

**Day 2: October 4, 2012**

8:30am  **Welcome, Recap of Day 1**

8:40am  **Consideration of Candidate Measures (Continued)**
• 0507: Stenosis measurement in carotid imaging studies (American Medical Association - Physician Consortium for Performance Improvement [AMA-PCPI])
• 2009: Dementia: Neuropsychiatric Symptom Assessment (AMA-PCPI)
• 2011: Dementia: Management of Neuropsychiatric Symptoms (AMA-PCPI)
• 2016: Dementia: Screening for Depressive Symptoms (AMA-PCPI)
• 1990: Dementia: Staging of Dementia (AMA-PCPI)
10:15am  Break

10:30am  Consideration of Candidate Measures (Continued)
  - 2000: Dementia: Cognitive Assessment (AMA-PCPI)
  - 2004: Dementia: Functional Status Assessment (AMA-PCPI)
  - 2028: Dementia: Counseling regarding Safety Concerns (AMA-PCPI)
  - 2029: Dementia: Counseling regarding Risks of Driving (AMA-PCPI)
  - 2030: Dementia: Caregiver Education and Support (AMA-PCPI)

11:45pm  NQF Member and Public Comment

12:00pm  Lunch

12:30pm  Additional Discussion Topics
  - Measure gaps
  - Disparities-sensitive measures

1:30pm  Additional Discussion Topics: Phase 1 Follow-Up
  - Discussion of comments received during second comment period on Yale/CMS Stroke Mortality & Readmissions measures

2:30pm  NQF Member and Public Comment

2:45pm  Next Steps/Committee Timeline

3:00pm  Adjourn